Tonix Pharmaceuticals Holding Corp (NAS:TNXP)

$ 0.1755 0.001 (0.57%) Market Cap: 16.77 Mil Enterprise Value: 19.54 Mil PE Ratio: 0 PB Ratio: 0.12 GF Score: 34/100

Tonix Pharmaceuticals Holding Corp to Host KOL Webinar Transcript
Jan 31, 2024
Tonix Pharmaceuticals Holding Corp at ThinkEquity Conference Transcript
Oct 19, 2023
Tonix Pharmaceuticals Holding Corp At The June 1st Virtual Investor Summit Transcript
Jun 01, 2023
Tonix Pharmaceuticals Holding Corp At Investor Summit (Virtual) Transcript
Mar 29, 2023
Tonix Pharmaceuticals announces acquisition of Healion Bio antiviral portfolio Transcript
Feb 23, 2023
Tonix Pharmaceuticals Holding Corpinterview with Dr. Seth Lederman, MD, and CEO Transcript
Feb 13, 2023
Tonix Pharmaceuticals discusses exclusive license of potential monoclonal antibodies Transcript
Feb 01, 2023
Tonix Pharmaceuticals Holding Corp at EBD Group Biotech Showcase Transcript
Jan 10, 2023
Tonix Pharmaceuticals Holding Corp at ThinkEquity Conference Transcript
Oct 26, 2022
Tonix Pharmaceuticals Holding Corp at Q2 Investor Summit Transcript
May 04, 2022
Tonix Pharmaceuticals Holding Corp at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript
Apr 27, 2022
Tonix Pharmaceuticals Holding Corp at Noble Capital Markets Investor Conference (Virtual) Transcript
Apr 21, 2022
Tonix Pharmaceuticals Holding Corp at Biotechnology Industry Organization (BIO) CEO & Investor Conference (Virtual) - Virtual Presentation Transcript
Feb 14, 2022
Tonix Pharmaceuticals Holding Corp at Raymond James Human Health Innovation Conference (Virtual) Transcript
Jun 23, 2021
Tonix Pharmaceuticals Holding Corp at ICR Virtual Conference Transcript
Jan 14, 2021
Tonix Pharmaceuticals Holding Corp Business Update Transcript
Dec 07, 2020
Tonix Pharmaceuticals Holding Corp at SNN Network Virtual Conference Transcript
Aug 06, 2020
Tonix Pharmaceuticals Holding Corp at SNN Planet MicroCap Showcase Transcript
Apr 29, 2020
Tonix Pharmaceuticals Holding Corp at SNN Planet MicroCap Showcase Transcript
Apr 22, 2020
Tonix Pharmaceuticals Holding Corp at Tarsier Capital Management Spring Summit Transcript
Mar 25, 2020
Tonix Pharmaceuticals Holding Corp at Noble Financial Emerging Growth Investor Conference Transcript
Feb 18, 2020

Tonix Pharmaceuticals Holding Corp at Q2 Investor Summit Transcript

May 04, 2022 / 03:00PM GMT

Release Date Price: $30.6 (+3.10%)

Transcript 10-Q8-K

Jessica Morris

Tonix Pharmaceuticals - COO

Thank you. Welcome everyone today to Tonix's presentation in the room today in person and also online with the webcast. I'm happy to be presenting today on behalf of Tonix. I am the Chief Operating Officer, Jessica Morris. So we are a publicly traded company on NASDAQ under the ticker TNXP. I will be making forward-looking statements as part of this presentation. So I would refer you to our SEC filings for complete information.

So Tonix Pharmaceuticals is a clinical stage biopharmaceutical company, and our mission is to advance the science and understanding of diseases by developing new therapies for health improvement of our population by focusing on unmet needs. And how do we do this? Our strategy is to use what we call our integrated development engine, our team of experienced professionals in preclinical, clinical, regulatory, CMC areas, all working together to take products from preclinical stage for development with the goal of FDA approval.

So these next few slides are Tonix's pipeline, and we have a broad pipeline. This is one of the

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.